CNS Pharma tries new therapeutic, financing approaches against glioblastoma
The Houston-based company is crowdfunding its way to providing new hope for glioblastoma patients.
Covidien’s pharma business buys CNS Therapeutics for $100 million
Mallinckrodt, the soon-to-be spun-out pharma business of Covidien, is buying a Minnesota company that is developing drugs to treat neurological disorders and severe chronic pain by delivering them to specific locations in the central nervous system. The Hazelwood, Missouri unit of Covidien announced Monday that it is acquiring CNS Therapeutics’ outstanding capital stock for $100 […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Minnesota drug developer CNS Therapeutics raises $3 million
On the heels of FDA approval of its new anti-spasticity drug Gablofen, CNS Therapeutics has raised $3 million in equity, according to documents filed with the Securities and Exchange Commission.
FDA approves CNS Therapeutics drug to treat movement disorder
Drug companies are rare in medical-device crazed Minnesota. Even more rare is a startup that can win approval from the Food and Drug Administration, given the cost and regulatory hurdles of pushing drugs to market, these days. So it’s heartening to see the FDA approval of Gablofen (who thinks of these names anyway?), a movement […]
Minnesota’s CNS Therapeutics raises $7 million
Previous investors InterWest Partners and Thomas McNerney Partners led the round. The company raised $6 million last year, according to filing with the Securities and Exchange Commission.